The latest price target for Unicycive Therapeutics (NASDAQ:UNCY) was reported by HC Wainwright & Co. on January 29, 2025. The analyst firm set a price target for $4.00 expecting UNCY to rise to within 12 months (a possible 545.27% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Unicycive Therapeutics (NASDAQ:UNCY) was provided by HC Wainwright & Co., and Unicycive Therapeutics reiterated their buy rating.

There is no last upgrade for Unicycive Therapeutics

There is no last downgrade for Unicycive Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unicycive Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unicycive Therapeutics was filed on January 29, 2025 so you should expect the next rating to be made available sometime around January 29, 2026.

While ratings are subjective and will change, the latest Unicycive Therapeutics (UNCY) rating was a reiterated with a price target of $4.00 to $4.00. The current price Unicycive Therapeutics (UNCY) is trading at is $0.62, which is out of the analyst’s predicted range.